{"type":"rich","version":"1.0","title":"Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio ","description":"In today's Pharmaceutical Executive Daily, Eli Lilly announces  a deal worth up to $202 million for Engage Biologics and its preclinical non-viral DNA delivery platform, two significant deals including Bristol Myers Squibb's enterprise-wide agreement to deploy Claude across its global operations and Incyte's expanded molecular AI collaboration with Genesis, and FDA grants two new early-stage breast cancer indications to Enhertu, marking trastuzumab deruxtecan's entry into the curative-intent setting for the first time.","author_name":"Pharmaceutical Executive","author_url":"https://audioboom.com/channels/5120049-pharmaceutical-executive","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43656062/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":"<iframe width=\"100%\" height=\"95\" src=\"https://embeds.audioboom.com/posts/8906035/embed?v=202301\" style=\"background-color: transparent; display: block; padding: 0; width: 100%\" frameborder=\"0\" allowtransparency=\"allowtransparency\" scrolling=\"no\" title=\"Audioboom player\" allow=\"autoplay\" sandbox=\"allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation\"></iframe>"}
